American College of Cardiology26d
A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity - SUMMIT
Highlighted text has been updated as of December 20, 2024. The SUMMIT trial showed that among obese patients with HFpEF, once weekly subcutaneous tirzepatide was superior to placebo in improving the ...
American College of Cardiology28d
ACCEL Lite: AHA Late-Breaker: SELECT – Semaglutide and CV Outcomes in Patients with Overweight or Obesity Who Do Not Have Diabetes
The SELECT trial extends findings from previous trials, which demonstrated cardiovascular benefit in diabetes mellitus (DM), to those without DM. In this interview, Abraham Lincoff, MD, FACC, and ...